http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 09:50:25 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Buy+Rating+on+Praxis+Precision+Medicines+Inc.+%28PRAX%29%3A+%22see+the+X-TOLE2+readout+as+having+no+readthrough%22/26130012.html <p>BTIG analyst Kambiz Yazdi reiterated a Buy rating and $843.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX)</p><p>The analyst commented, "We admit the azetukalner (XENE, Not Rated) results are impressive, but see the X-TOLE2 readout as having no readthrough to PRAX. The majority of the PRAX's stock value is tied to ulixa in ET, with relutrigine for DEEs second, followed by vormatrigine in FOS. While azetukalner is a significant advancement for the Kv7 channel opener class we do not view it as a new mechanism. Vormatrigine, stands toe-to-toe showing a 54% median reduction in FOS patients taking the drug http://www.streetinsider.com/Analyst+Comments/BTIG+Reiterates+Buy+Rating+on+Praxis+Precision+Medicines+Inc.+%28PRAX%29%3A+%22see+the+X-TOLE2+readout+as+having+no+readthrough%22/26130012.html Mon, 09 Mar 2026 09:50:25 -0400 PRAX http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Press+Releases/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html <p align="left">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule http://www.streetinsider.com/Globe+Newswire/Praxis+Precision+Medicines%2C+Inc.+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26110793.html Wed, 04 Mar 2026 16:01:00 -0400 A.40189063 O.00966563 O.48989252 PRAX http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html <p>Wolfe Research analyst Rudy Li initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Outperform rating and a price target of $500.00.</p><p>The analyst comments "2026 would be a transformative year for PRAX - We believe the company would be able to build up 2 strong franchises of essential tremor (ET) and epilepsy ➢ The company could have 2 products approved in 2026 (2 NDAs filed in Feb): ➢ Lead asset ulixacaltamide reported strongly positive ET data from Ph3 Essential3 (Study 1 and 2) , with BTD granted – It would be the only player in the large ET http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html Tue, 24 Feb 2026 08:58:27 -0400 PRAX http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html <p>Wolfe Research analyst Rudy Li initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Outperform rating and a price target of $500.00.</p><p>The analyst comments "2026 would be a transformative year for PRAX - We believe the company would be able to build up 2 strong franchises of essential tremor (ET) and epilepsy ➢ The company could have 2 products approved in 2026 (2 NDAs filed in Feb): ➢ Lead asset ulixacaltamide reported strongly positive ET data from Ph3 Essential3 (Study 1 and 2) , with BTD granted – It would be the only player in the large ET http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html Tue, 24 Feb 2026 08:58:27 -0400 PRAX http://www.streetinsider.com/Hot+Comments/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html <p>Wolfe Research analyst Rudy Li initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Outperform rating and a price target of $500.00.</p><p>The analyst comments "2026 would be a transformative year for PRAX - We believe the company would be able to build up 2 strong franchises of essential tremor (ET) and epilepsy ➢ The company could have 2 products approved in 2026 (2 NDAs filed in Feb): ➢ Lead asset ulixacaltamide reported strongly positive ET data from Ph3 Essential3 (Study 1 and 2) , with BTD granted – It would be the only player in the large ET http://www.streetinsider.com/Hot+Comments/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html Tue, 24 Feb 2026 08:58:27 -0400 PRAX http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html <p>Wolfe Research analyst Rudy Li initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Outperform rating and a price target of $500.00.</p><p>The analyst comments "2026 would be a transformative year for PRAX - We believe the company would be able to build up 2 strong franchises of essential tremor (ET) and epilepsy ➢ The company could have 2 products approved in 2026 (2 NDAs filed in Feb): ➢ Lead asset ulixacaltamide reported strongly positive ET data from Ph3 Essential3 (Study 1 and 2) , with BTD granted – It would be the only player in the large ET http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Praxis+Precision+Medicines+Inc.+%28PRAX%29+at+Outperform%2C+Top+Pick/26043128.html Tue, 24 Feb 2026 08:58:27 -0400 PRAX http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24130+at+Wedbush/26033117.html Wedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $130.00 (from $95.00) while maintaining a Underperform rating. http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24130+at+Wedbush/26033117.html Fri, 20 Feb 2026 07:51:59 -0400 PRAX http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24412+at+Deutsche+Bank/26033111.html Deutsche Bank analyst David Hoang raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $412.00 (from $357.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24412+at+Deutsche+Bank/26033111.html Fri, 20 Feb 2026 07:50:09 -0400 PRAX http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24433+at+Baird/26033052.html Baird analyst Brian Skorney raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $433.00 (from $275.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24433+at+Baird/26033052.html Fri, 20 Feb 2026 07:41:47 -0400 PRAX http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24305+at+Wells+Fargo/26032880.html Wells Fargo raised its price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $305.00 (from $282.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/Praxis+Precision+Medicines+Inc.+%28PRAX%29+PT+Raised+to+%24305+at+Wells+Fargo/26032880.html Fri, 20 Feb 2026 07:09:33 -0400 PRAX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Praxis+Precision+Medicin+++++++++++++/26027111.html si-local-file:///var/storage/secattach/20260219/26027111.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Praxis+Precision+Medicin+++++++++++++/26027111.html Thu, 19 Feb 2026 09:06:00 -0400 O.48989252 PRAX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Praxis+Precision+Medicin+++++++++++++/26027111.html si-local-file:///var/storage/secattach/20260219/26027111.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Praxis+Precision+Medicin+++++++++++++/26027111.html Thu, 19 Feb 2026 09:06:00 -0400 O.48989252 PRAX http://www.streetinsider.com/Analyst+Comments/Truist+on+Praxis+Precision+Medicines+Inc.+%28PRAX%29%3A+%27We+see+Significant+Upside+Potential+To+Our+Base+Case%27/26026774.html <p>Truist Securities analyst Joon Lee reiterated a Buy rating and $500.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).</p><p>The analyst commented: "Payor KOL Call Takeaways On Ulixa For ET. We see Significant Upside Potential To Our Base Case; We currently model launch WAC price of ~$27K/yr (20K net pricing, i.e. ~25% rebate) based on price of branded beta-blockers. However, KOLs felt comfortable with up to ~$35K on net-pricing, which implies ~$50K/yr WAC for ulixa or ~75% upside to our base case ulixa pricing."</p><p>For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. <a href="http://www.streetinsider.com/rating_history.php?q=PRAX">click here</a>. For http://www.streetinsider.com/Analyst+Comments/Truist+on+Praxis+Precision+Medicines+Inc.+%28PRAX%29%3A+%27We+see+Significant+Upside+Potential+To+Our+Base+Case%27/26026774.html Thu, 19 Feb 2026 08:48:17 -0400 PRAX http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Praxis+Precision+Medicin++For%3A+Dec+31/26026380.html si-local-file:///var/storage/secattach/20260219/26026380.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Praxis+Precision+Medicin++For%3A+Dec+31/26026380.html Thu, 19 Feb 2026 08:03:00 -0400 O.48989252 PRAX http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Praxis+Precision+Medicin++For%3A+Dec+31/26026380.html si-local-file:///var/storage/secattach/20260219/26026380.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Praxis+Precision+Medicin++For%3A+Dec+31/26026380.html Thu, 19 Feb 2026 08:03:00 -0400 O.48989252 PRAX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Praxis+Precision+Medicin++For%3A+Feb+19/26026357.html si-local-file:///var/storage/secattach/20260219/26026357.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Praxis+Precision+Medicin++For%3A+Feb+19/26026357.html Thu, 19 Feb 2026 08:01:00 -0400 O.48989252 PRAX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Praxis+Precision+Medicin++For%3A+Feb+19/26026357.html si-local-file:///var/storage/secattach/20260219/26026357.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Praxis+Precision+Medicin++For%3A+Feb+19/26026357.html Thu, 19 Feb 2026 08:01:00 -0400 O.48989252 PRAX http://www.streetinsider.com/Earnings/Praxis+Precision+Medicines+%28PRAX%29+Misses+Q4+EPS+by+41c/26026061.html <p>Praxis Precision Medicines (NASDAQ: PRAX) reported Q4 EPS of ($3.50), $0.41 worse than the analyst estimate of ($3.09).</p><p>For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) <a href="http://www.streetinsider.com/ec_earnings.php?q=PRAX">click here</a>.</p> http://www.streetinsider.com/Earnings/Praxis+Precision+Medicines+%28PRAX%29+Misses+Q4+EPS+by+41c/26026061.html Thu, 19 Feb 2026 07:33:17 -0400 PRAX